Clinical Trial Update: Pazopanib in Relapsed and Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of pazopanib for relapsed and refractory small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: SCLC | Phase 2 | Status: COMPLETED